<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Public Health</journal-id><journal-title>BMC Public Health</journal-title><issn pub-type="epub">1471-2458</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17210069</article-id><article-id pub-id-type="pmc">1779771</article-id><article-id pub-id-type="publisher-id">1471-2458-7-4</article-id><article-id pub-id-type="doi">10.1186/1471-2458-7-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Application of adenosine 5'-triphosphate (ATP) infusions in palliative home care: design of a randomized clinical trial</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Beijer</surname><given-names>Sandra</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>sandra.beijer@epid.unimaas.nl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>van Rossum</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>erik.vanrossum@zw.unimaas.nl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Hupperets</surname><given-names>Pierre S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>phu@sint.azm.nl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Spreeuwenberg</surname><given-names>Cor</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>c.spreeuwenberg@zw.unimaas.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>van den Beuken</surname><given-names>Marieke</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>mvdb@adcc.azm.nl</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Winkens</surname><given-names>Ron A</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>ron.winkens@HAG.unimaas.nl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Ars</surname><given-names>Lisette</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>l.ars@gkzorg.nl</email></contrib><contrib id="A8" contrib-type="author"><name><surname>van den Borne</surname><given-names>Ben E</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>ben.vd.borne@catharina-ziekenhuis.nl</email></contrib><contrib id="A9" contrib-type="author"><name><surname>de Graeff</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>a.graeff@digd.azu.nl</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Dagnelie</surname><given-names>Pieter C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>dagnelie@epid.unimaas.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Epidemiology, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands</aff><aff id="I2"><label>2</label>Department of Internal Medicine/Oncology, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</aff><aff id="I3"><label>3</label>Department of Health Care Studies, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands</aff><aff id="I4"><label>4</label>Pain Management and Research Centre, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</aff><aff id="I5"><label>5</label>Department of Integrated Care, University Hospital Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands</aff><aff id="I6"><label>6</label>Community Care Organisation, GroenekruisDomicura Maastricht and area, Mockstraat 1, 6226 CA Maastricht, The Netherlands</aff><aff id="I7"><label>7</label>Department of Pulmonology, Catharina Hospital Eindhoven, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands</aff><aff id="I8"><label>8</label>Department of Internal Medicine/Medical Oncology, University Medical Center Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>8</day><month>1</month><year>2007</year></pub-date><volume>7</volume><fpage>4</fpage><lpage>4</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2458/7/4"></ext-link><history><date date-type="received"><day>16</day><month>11</month><year>2006</year></date><date date-type="accepted"><day>8</day><month>1</month><year>2007</year></date></history><permissions><copyright-statement>Copyright Â© 2007 Beijer et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Beijer et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="5347" xml_f="5357" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5368" xml_f="6011" txt_i="22" txt_f="665">Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status and quality of life. The present study was designed 1. To evaluate whether ATP has favourable effects in terminally ill cancer patients, 2. To evaluate whether ATP infusions may reduce family caregiver burden and reduce the use of professional health care services, and 3. To test the feasibility of application of ATP infusions in a home care setting.</offsets></p></sec><sec><title><offsets xml_i="6033" xml_f="6047" txt_i="667" txt_f="681">Methods/Design</offsets></title><p><offsets xml_i="6058" xml_f="6516" txt_i="682" txt_f="1140">The study can be characterized as an open-labelled randomized controlled trial with two parallel groups. The intervention group received usual palliative care, two visits by an experienced dietician for advice, and regular ATP infusions over a period of 8 weeks. The control group received palliative care as usual and dietetic advice, but no ATP. This paper gives a description of the study design, selection of patients, interventions and outcome measures.</offsets></p></sec><sec><title><offsets xml_i="6538" xml_f="6548" txt_i="1142" txt_f="1152">Discussion</offsets></title><p><offsets xml_i="6559" xml_f="6962" txt_i="1153" txt_f="1556">From April 2002 through October 2006, a total of 100 patients have been randomized. Follow-up of patients will be completed in December 2006. At the time of writing, five patients are still in follow up. Of the 95 patients who have completed the study, 69 (73%) have completed four weeks of follow-up, and 53 (56%) have completed the full eight-week study period. The first results are expected in 2007.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="7024" xml_f="7034" txt_i="1565" txt_f="1575">Background</offsets></title><p><offsets xml_i="7045" xml_f="7205" txt_i="1576" txt_f="1736">The World Health Organisation noted that 'the ultimate goal of palliative care is the achievement of the best quality of life for patients and their families' [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7236" xml_f="7237" txt_i="1736" txt_f="1737">1</offsets></xref><offsets xml_i="7244" xml_f="7498" txt_i="1737" txt_f="1991">]. Complaints like progressive fatigue, deterioration in performance status, weight loss and reduced functional abilities have a substantial impact on the quality of life, and also lead to frequent and intensive use of professional health care services [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7529" xml_f="7530" txt_i="1991" txt_f="1992">2</offsets></xref><offsets xml_i="7537" xml_f="7538" txt_i="1992" txt_f="1993">,</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7569" xml_f="7570" txt_i="1993" txt_f="1994">3</offsets></xref><offsets xml_i="7577" xml_f="7709" txt_i="1994" txt_f="2126">]. It is therefore important to develop therapies that contribute to the alleviation of these complaints in terminally ill patients.</offsets></p><p><offsets xml_i="7716" xml_f="7907" txt_i="2127" txt_f="2318">Adenosine 5'-triphosphate (ATP) is a naturally occurring purine nucleotide which is present in every cell of the human body, well-known because of its intracellular energy-transferring role [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="7938" xml_f="7939" txt_i="2318" txt_f="2319">4</offsets></xref><offsets xml_i="7946" xml_f="8177" txt_i="2319" txt_f="2550">]. Furthermore, extracellular ATP is involved in the regulation of a variety of biological processes such as neurotransmission, muscle contraction, cardiac function, platelet function, vasodilatation, and liver glucose metabolism [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8208" xml_f="8209" txt_i="2550" txt_f="2551">4</offsets></xref><offsets xml_i="8216" xml_f="8525" txt_i="2551" txt_f="2860">]. A previous randomized clinical trial in 58 patients with advanced non-small-cell lung cancer (NSCLC) showed that 10 intravenous 30-hour ATP infusions every 2 to 4 weeks in a clinical setting had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status and quality of life [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="8556" xml_f="8557" txt_i="2860" txt_f="2861">5</offsets></xref><offsets xml_i="8564" xml_f="8743" txt_i="2861" txt_f="3040">]. Side effects (mainly chest discomfort, dyspnea and urge to take a deep breath) observed during ATP infusion were mild and disappeared rapidly after lowering the infusion rate [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8774" xml_f="8775" txt_i="3040" txt_f="3041">6</offsets></xref><offsets xml_i="8782" xml_f="8784" txt_i="3041" txt_f="3043">].</offsets></p><p><offsets xml_i="8791" xml_f="9134" txt_i="3044" txt_f="3387">Considering the relatively mild character of ATP therapy, application of ATP infusions in palliative home care might be a promising and relatively simple treatment to improve the quality of life and functional status of patients with advanced cancer. Based on this consideration, we initiated a study in terminally ill cancer patients, aiming:</offsets></p><p><offsets xml_i="9141" xml_f="9225" txt_i="3388" txt_f="3472">1. To evaluate whether ATP has favourable effects in terminally ill cancer patients,</offsets></p><p><offsets xml_i="9232" xml_f="9364" txt_i="3473" txt_f="3605">2. To evaluate whether ATP infusions may reduce family caregiver burden and reduce the use of professional health care services, and</offsets></p><p><offsets xml_i="9371" xml_f="9453" txt_i="3606" txt_f="3688">3. To test the feasibility of application of ATP infusions in a home care setting.</offsets></p><p><offsets xml_i="9460" xml_f="9577" txt_i="3689" txt_f="3806">In the present paper, we describe the design, selection of patients, intervention and outcome measures of this study.</offsets></p></sec><sec><title><offsets xml_i="9599" xml_f="9613" txt_i="3808" txt_f="3822">Methods/Design</offsets></title><sec><title><offsets xml_i="9633" xml_f="9665" txt_i="3823" txt_f="3855">Study design and general outline</offsets></title><p><offsets xml_i="9676" xml_f="9683" txt_i="3856" txt_f="3863">Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="9713" xml_f="9714" txt_i="3863" txt_f="3864">1</offsets></xref><offsets xml_i="9721" xml_f="10727" txt_i="3864" txt_f="4870"> displays the outline of the study design. The study can be characterized as an open-labelled randomized controlled trial with two parallel groups. Patients eligible for the study were, after stratification, randomly allocated to the intervention or control group. The intervention group received palliative care as usual and two visits by an experienced dietician for advice, and regular ATP infusions over a period of 8 weeks. The control group received palliative care as usual and dietetic advice, but no ATP. Primary and secondary outcomes were assessed at baseline and every two weeks thereafter, until eight weeks after randomization. To minimize patient burden, all outcome measurements were taken at the patients' home. Part of the data were collected with assistance from the patients' partner or family caregiver (e.g. dietary record, medication, use of professional care services). The study was approved by the Ethical Committee of the University Hospital Maastricht and Maastricht University.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="10768" xml_f="10776" txt_i="4871" txt_f="4879">Figure 1</offsets></label><caption><p><offsets xml_i="10796" xml_f="10809" txt_i="4879" txt_f="4892">Study design.</offsets></p></caption><graphic xlink:href="1471-2458-7-4-1"></graphic></fig></sec><sec><title><offsets xml_i="10895" xml_f="10911" txt_i="4894" txt_f="4910">Study population</offsets></title><p><offsets xml_i="10922" xml_f="11665" txt_i="4911" txt_f="5645">Eligible were patients with cytologically or histologically confirmed cancer, for whom medical treatment options were restricted to supportive care, who had a life expectancy &lt; 6 months, had a World Health Organization (WHO) performance status 1 or 2, and suffered from at least one of the following complaints: fatigue, weight loss &gt; 5% over the last 6 months, or anorexia. Patients with a WHO performance status &gt; 2 were excluded because they were not able to attend the clinic and to undergo antropometric and muscle strength measurements. Furthermore, patients with symptomatic angina pectoris, symptomatic heart failure or any form of atrioventricular (AV) block (assessed by electrocardiogram) were excluded for safety reasons [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="11696" xml_f="11697" txt_i="5645" txt_f="5646">7</offsets></xref><offsets xml_i="11704" xml_f="11705" txt_i="5646" txt_f="5647">,</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="11736" xml_f="11737" txt_i="5647" txt_f="5648">8</offsets></xref><offsets xml_i="11744" xml_f="12056" txt_i="5648" txt_f="5957">]. Other exclusion criteria were: life expectancy &lt; 4 weeks, concurrent palliative chemotherapy, cognitive dysfunction, and other diseases hampering adequate follow up. The eligibility of patients was evaluated by a medical oncologist before inclusion. Written informed consent was obtained from all patients.</offsets></p><sec><title><offsets xml_i="12072" xml_f="12091" txt_i="5958" txt_f="5977">Patient recruitment</offsets></title><p><offsets xml_i="12102" xml_f="12578" txt_i="5978" txt_f="6454">Patients were recruited through the Departments of Medical Oncology and Pulmonology of five hospitals in different regions in the Netherlands (Maastricht, Heerlen, Eindhoven and Utrecht). When the last line of chemotherapy had failed and medical treatment options were restricted to supportive care, the patient was informed about the study by the oncologist or pulmonologist. In addition, general practitioners in the region of Maastricht participated in patient recruitment.</offsets></p></sec></sec><sec><title><offsets xml_i="12606" xml_f="12619" txt_i="6457" txt_f="6470">Randomisation</offsets></title><p><offsets xml_i="12630" xml_f="12951" txt_i="6471" txt_f="6792">After baseline measurements, patients were randomly allocated to the treatment group, using random numbers generated by computer with a permuted block size of four. Before randomization participants were stratified for tumor type (colon cancer, breast cancer, and other types of cancer) and weight loss (â¤ 5% in 6 months </offsets><italic><offsets xml_i="12959" xml_f="12961" txt_i="6792" txt_f="6794">vs</offsets></italic><offsets xml_i="12970" xml_f="13095" txt_i="6794" txt_f="6916">. &gt; 5%), since weight loss is an important prognostic factor for deterioration of physical condition and quality of life [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="13126" xml_f="13127" txt_i="6916" txt_f="6917">9</offsets></xref><offsets xml_i="13134" xml_f="13136" txt_i="6917" txt_f="6919">].</offsets></p></sec><sec><title><offsets xml_i="13158" xml_f="13170" txt_i="6921" txt_f="6933">Intervention</offsets></title><sec><title><offsets xml_i="13190" xml_f="13197" txt_i="6934" txt_f="6941">General</offsets></title><p><offsets xml_i="13208" xml_f="14144" txt_i="6942" txt_f="7878">Patients in both the experimental and control group received care as usual, i.e. patients were allowed to use and apply for all available health care services. As an additional support for patients both in the intervention and control group, all patients were visited at home by an experienced dietician in week 2 and 6 of the study. At these visits, using a standard checklist, problems and complaints were noted and followed by standard nutritional advice based on the type of complaints of the patient. For this purpose, information sheets were designed containing a standard nutritional advice for any of the following complaints: weight loss, anorexia, food aversions, nausea and vomiting, swallowing problems, dry mouth, painful mouth, diarrhoea, and obstipation. In case patients asked for more intensive dietary support or for specific nutritional supplements, they were referred to a regular dietician in hospital or home care.</offsets></p></sec><sec><title><offsets xml_i="14166" xml_f="14169" txt_i="7880" txt_f="7883">ATP</offsets></title><p><offsets xml_i="14180" xml_f="14444" txt_i="7884" txt_f="8148">Patients allocated to the experimental study group received weekly ATP infusions over a period of eight weeks. A longer infusion period was not considered feasible in these patients because of the expected rapidly deteriorating condition of participating patients.</offsets></p><p><offsets xml_i="14451" xml_f="14566" txt_i="8149" txt_f="8264">In our previous study in NSCLC patients, 10 intravenous 30-hour ATP infusions were given at 2 to 4-week intervals [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="14597" xml_f="14598" txt_i="8264" txt_f="8265">5</offsets></xref><offsets xml_i="14605" xml_f="15502" txt_i="8265" txt_f="9162">]. Because of the advanced disease stage in the present study, a less intensive treatment schedule of 10 hours (range 8 â 12 hours) was chosen, in order to avoid ATP administration during the night or an overnight stay at the hospital. To increase the overall ATP dose given, ATP was administered on a weekly basis. A dose of 50 mcg/kg.min, or lower when side effects occurred, was chosen in order to maximize safety at home; in our previous study a large proportion of patients did not tolerate the dose of 75 mcg/kg.min. ATP infusions were started beginning at a dose of 20 mcg/kg.min, and were increased in steps of 10 mcg/kg.min every 10 minutes until a maximum dose of 50 mcg/kg.min, or until the maximally tolerated dose, if this was lower, had been reached. Thereafter, ATP was infused at a continuous rate. If any side effects occurred, the dose was reduced until side effects disappeared.</offsets></p><p><offsets xml_i="15509" xml_f="16558" txt_i="9163" txt_f="10212">In the previous study ATP infusions were given in a clinical setting under strict medical supervision. Since patients in the present study were in a considerably later stage of disease, with consequently a shorter life expectancy, the majority of patients was supported by the general practitioner and were discharged from routine specialist care, with only occasional visits to the out-patient clinic, when necessary. For this reason, it was decided to basically administer most of the ATP infusions in the home setting. However, since initiation of ATP infusions under medical supervision in a clinical setting would facilitate the treatment of possible side effects, the first two ATP infusions were given at the day care center of the participating hospitals. Based on the mild character of the noted side effects during the first two infusions in the first 22 patients, an amendment was granted by the Ethical Committee during the study for administering only the first ATP infusion at the day care center, and all subsequent infusions at home.</offsets></p><p><offsets xml_i="16565" xml_f="17456" txt_i="10213" txt_f="11104">At the end of the first infusion, the safety and tolerated dose of ATP was evaluated for each individual patient. Subsequent infusions were given at the patients' home by an experienced and trained nurse of the infusion team of the Community Care Organization. The maximally tolerated dose during the first infusion at the day care center was also the maximum dose for the next infusions at home. At home, ATP infusions also started with a dose of 20 mcg/kg.min and increased in steps of 10 mcg/kg.min every 10 minutes until the maximum tolerated dose had been reached. To provide maximal mobility a portable infusion pump was used during ATP administration. Patients and their partners were instructed extensively regarding the infusion procedures and to call the infusion team of the Community Health Care Organisation in case of side effects or other problems, such as technical problems.</offsets></p></sec><sec><title><offsets xml_i="17478" xml_f="17509" txt_i="11106" txt_f="11137">Side effects and adverse events</offsets></title><p><offsets xml_i="17520" xml_f="17878" txt_i="11138" txt_f="11496">Side effects of all ATP infusions, adjustments of dosage schedules, and any other problems occurring during the infusions were registered systematically on a standard form by the medical and nursing staff of the day care center of the participating hospitals, the nurses of the home infusion teams and the researcher according to WHO Common Toxity Criteria [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="17910" xml_f="17912" txt_i="11496" txt_f="11498">10</offsets></xref><offsets xml_i="17919" xml_f="17921" txt_i="11498" txt_f="11500">].</offsets></p><p><offsets xml_i="17928" xml_f="18365" txt_i="11501" txt_f="11938">Any adverse event that occurred from baseline until one week after the last ATP infusion was reported by the investigator on the appropiate Case Report Form. Patients and their caregivers were instructed to contact the investigator if an adverse event occurred. All serious adverse events that were unexpected and assessed to be related to the study product were to be reported to the principal investigator of the study within 24 hours.</offsets></p></sec></sec><sec><title><offsets xml_i="18393" xml_f="18411" txt_i="11941" txt_f="11959">Outcome assessment</offsets></title><p><offsets xml_i="18422" xml_f="18501" txt_i="11960" txt_f="12039">Most of the outcome measures were adapted from the study from Agteresch et al [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="18532" xml_f="18533" txt_i="12039" txt_f="12040">5</offsets></xref><offsets xml_i="18540" xml_f="18542" txt_i="12040" txt_f="12042">].</offsets></p><sec><title><offsets xml_i="18558" xml_f="18582" txt_i="12043" txt_f="12067">Primary outcome measures</offsets></title><p><italic><offsets xml_i="18601" xml_f="18626" txt_i="12068" txt_f="12093">Primary outcome measures </offsets></italic><offsets xml_i="18635" xml_f="18701" txt_i="12093" txt_f="12159">were quality of life, fatigue and physical restriction (see Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="18733" xml_f="18734" txt_i="12159" txt_f="12160">1</offsets></xref><offsets xml_i="18741" xml_f="18743" txt_i="12160" txt_f="12162">).</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="18791" xml_f="18798" txt_i="12163" txt_f="12170">Table 1</offsets></label><caption><p><offsets xml_i="18818" xml_f="18853" txt_i="12170" txt_f="12205">Time schedule of outcome assessment</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold><offsets xml_i="18938" xml_f="18953" txt_i="12206" txt_f="12221">Outcome measure</offsets></bold></td><td align="left"><bold><offsets xml_i="18988" xml_f="19022" txt_i="12222" txt_f="12256">Measurement scale or specification</offsets></bold></td><td align="left" colspan="5"><bold><offsets xml_i="19069" xml_f="19086" txt_i="12257" txt_f="12274">Timing (in weeks)</offsets></bold></td></tr></thead><tbody><tr><td align="left"><bold><offsets xml_i="19145" xml_f="19161" txt_i="12275" txt_f="12291">Primary outcomes</offsets></bold></td><td></td><td align="center"><bold><offsets xml_i="19207" xml_f="19208" txt_i="12293" txt_f="12294">0</offsets></bold></td><td align="center"><bold><offsets xml_i="19245" xml_f="19246" txt_i="12295" txt_f="12296">2</offsets></bold></td><td align="center"><bold><offsets xml_i="19283" xml_f="19284" txt_i="12297" txt_f="12298">4</offsets></bold></td><td align="center"><bold><offsets xml_i="19321" xml_f="19322" txt_i="12299" txt_f="12300">6</offsets></bold></td><td align="center"><bold><offsets xml_i="19359" xml_f="19360" txt_i="12301" txt_f="12302">8</offsets></bold></td></tr><tr><td align="left"><offsets xml_i="19398" xml_f="19413" txt_i="12303" txt_f="12318">Quality of Life</offsets></td><td align="left"><offsets xml_i="19435" xml_f="19449" txt_i="12319" txt_f="12333">EORTC QLQ-C30*</offsets></td><td align="center"><offsets xml_i="19473" xml_f="19474" txt_i="12334" txt_f="12335">X</offsets></td><td></td><td align="center"><offsets xml_i="19507" xml_f="19508" txt_i="12337" txt_f="12338">X</offsets></td><td></td><td align="center"><offsets xml_i="19541" xml_f="19542" txt_i="12340" txt_f="12341">X</offsets></td></tr><tr><td align="left"><offsets xml_i="19573" xml_f="19588" txt_i="12342" txt_f="12357">Quality of Life</offsets></td><td align="left"><offsets xml_i="19610" xml_f="19635" txt_i="12358" txt_f="12383">RSCL, overall question **</offsets></td><td align="center"><offsets xml_i="19659" xml_f="19660" txt_i="12384" txt_f="12385">X</offsets></td><td align="center"><offsets xml_i="19684" xml_f="19685" txt_i="12386" txt_f="12387">X</offsets></td><td align="center"><offsets xml_i="19709" xml_f="19710" txt_i="12388" txt_f="12389">X</offsets></td><td align="center"><offsets xml_i="19734" xml_f="19735" txt_i="12390" txt_f="12391">X</offsets></td><td align="center"><offsets xml_i="19759" xml_f="19760" txt_i="12392" txt_f="12393">X</offsets></td></tr><tr><td align="left"><offsets xml_i="19791" xml_f="19798" txt_i="12394" txt_f="12401">Fatigue</offsets></td><td align="left"><offsets xml_i="19820" xml_f="19826" txt_i="12402" txt_f="12408">SFQ***</offsets></td><td align="center"><offsets xml_i="19850" xml_f="19851" txt_i="12409" txt_f="12410">X</offsets></td><td align="center"><offsets xml_i="19875" xml_f="19876" txt_i="12411" txt_f="12412">X</offsets></td><td align="center"><offsets xml_i="19900" xml_f="19901" txt_i="12413" txt_f="12414">X</offsets></td><td align="center"><offsets xml_i="19925" xml_f="19926" txt_i="12415" txt_f="12416">X</offsets></td><td align="center"><offsets xml_i="19950" xml_f="19951" txt_i="12417" txt_f="12418">X</offsets></td></tr><tr><td align="left"><offsets xml_i="19982" xml_f="20002" txt_i="12419" txt_f="12439">Physical restriction</offsets></td><td align="left"><offsets xml_i="20024" xml_f="20034" txt_i="12440" txt_f="12450">GARS-4****</offsets></td><td align="center"><offsets xml_i="20058" xml_f="20059" txt_i="12451" txt_f="12452">X</offsets></td><td align="center"><offsets xml_i="20083" xml_f="20084" txt_i="12453" txt_f="12454">X</offsets></td><td align="center"><offsets xml_i="20108" xml_f="20109" txt_i="12455" txt_f="12456">X</offsets></td><td align="center"><offsets xml_i="20133" xml_f="20134" txt_i="12457" txt_f="12458">X</offsets></td><td align="center"><offsets xml_i="20158" xml_f="20159" txt_i="12459" txt_f="12460">X</offsets></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><offsets xml_i="20268" xml_f="20286" txt_i="12468" txt_f="12486">Secundary outcomes</offsets></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="20378" xml_f="20386" txt_i="12493" txt_f="12501">Appetite</offsets></td><td align="left"><offsets xml_i="20408" xml_f="20430" txt_i="12502" txt_f="12524">Appetite Questionnaire</offsets></td><td align="center"><offsets xml_i="20454" xml_f="20455" txt_i="12525" txt_f="12526">X</offsets></td><td></td><td align="center"><offsets xml_i="20488" xml_f="20489" txt_i="12528" txt_f="12529">X</offsets></td><td></td><td align="center"><offsets xml_i="20522" xml_f="20523" txt_i="12531" txt_f="12532">X</offsets></td></tr><tr><td align="left"><offsets xml_i="20554" xml_f="20572" txt_i="12533" txt_f="12551">Nutritional intake</offsets></td><td align="left"><offsets xml_i="20594" xml_f="20610" txt_i="12552" txt_f="12568">3-Day food diary</offsets></td><td align="center"><offsets xml_i="20634" xml_f="20635" txt_i="12569" txt_f="12570">X</offsets></td><td></td><td align="center"><offsets xml_i="20668" xml_f="20669" txt_i="12572" txt_f="12573">X</offsets></td><td></td><td align="center"><offsets xml_i="20702" xml_f="20703" txt_i="12575" txt_f="12576">X</offsets></td></tr><tr><td align="left"><offsets xml_i="20734" xml_f="20744" txt_i="12577" txt_f="12587">Medication</offsets></td><td align="left"><offsets xml_i="20766" xml_f="20781" txt_i="12588" txt_f="12603">Medication list</offsets></td><td align="center"><offsets xml_i="20805" xml_f="20806" txt_i="12604" txt_f="12605">X</offsets></td><td align="center"><offsets xml_i="20830" xml_f="20831" txt_i="12606" txt_f="12607">X</offsets></td><td align="center"><offsets xml_i="20855" xml_f="20856" txt_i="12608" txt_f="12609">X</offsets></td><td align="center"><offsets xml_i="20880" xml_f="20881" txt_i="12610" txt_f="12611">X</offsets></td><td align="center"><offsets xml_i="20905" xml_f="20906" txt_i="12612" txt_f="12613">X</offsets></td></tr><tr><td align="left"><offsets xml_i="20937" xml_f="20948" txt_i="12614" txt_f="12625">Body weight</offsets></td><td align="left"><offsets xml_i="20970" xml_f="20995" txt_i="12626" txt_f="12651">Electronic weighing scale</offsets></td><td align="center"><offsets xml_i="21019" xml_f="21020" txt_i="12652" txt_f="12653">X</offsets></td><td align="center"><offsets xml_i="21044" xml_f="21045" txt_i="12654" txt_f="12655">X</offsets></td><td align="center"><offsets xml_i="21069" xml_f="21070" txt_i="12656" txt_f="12657">X</offsets></td><td align="center"><offsets xml_i="21094" xml_f="21095" txt_i="12658" txt_f="12659">X</offsets></td><td align="center"><offsets xml_i="21119" xml_f="21120" txt_i="12660" txt_f="12661">X</offsets></td></tr><tr><td align="left"><offsets xml_i="21151" xml_f="21167" txt_i="12662" txt_f="12678">Triceps skinfold</offsets></td><td></td><td align="center"><offsets xml_i="21200" xml_f="21201" txt_i="12680" txt_f="12681">X</offsets></td><td align="center"><offsets xml_i="21225" xml_f="21226" txt_i="12682" txt_f="12683">X</offsets></td><td align="center"><offsets xml_i="21250" xml_f="21251" txt_i="12684" txt_f="12685">X</offsets></td><td align="center"><offsets xml_i="21275" xml_f="21276" txt_i="12686" txt_f="12687">X</offsets></td><td align="center"><offsets xml_i="21300" xml_f="21301" txt_i="12688" txt_f="12689">X</offsets></td></tr><tr><td align="left"><offsets xml_i="21332" xml_f="21349" txt_i="12690" txt_f="12707">Arm circumference</offsets></td><td></td><td align="center"><offsets xml_i="21382" xml_f="21383" txt_i="12709" txt_f="12710">X</offsets></td><td align="center"><offsets xml_i="21407" xml_f="21408" txt_i="12711" txt_f="12712">X</offsets></td><td align="center"><offsets xml_i="21432" xml_f="21433" txt_i="12713" txt_f="12714">X</offsets></td><td align="center"><offsets xml_i="21457" xml_f="21458" txt_i="12715" txt_f="12716">X</offsets></td><td align="center"><offsets xml_i="21482" xml_f="21483" txt_i="12717" txt_f="12718">X</offsets></td></tr><tr><td align="left"><offsets xml_i="21514" xml_f="21529" txt_i="12719" txt_f="12734">Muscle strength</offsets></td><td align="left"><offsets xml_i="21551" xml_f="21581" txt_i="12735" txt_f="12765">Biceps and quadriceps strength</offsets></td><td align="center"><offsets xml_i="21605" xml_f="21606" txt_i="12766" txt_f="12767">X</offsets></td><td></td><td align="center"><offsets xml_i="21639" xml_f="21640" txt_i="12769" txt_f="12770">X</offsets></td><td></td><td align="center"><offsets xml_i="21673" xml_f="21674" txt_i="12772" txt_f="12773">X</offsets></td></tr><tr><td align="left"><offsets xml_i="21705" xml_f="21720" txt_i="12774" txt_f="12789">Muscle strength</offsets></td><td align="left"><offsets xml_i="21742" xml_f="21759" txt_i="12790" txt_f="12807">Handgrip strength</offsets></td><td align="center"><offsets xml_i="21783" xml_f="21784" txt_i="12808" txt_f="12809">X</offsets></td><td align="center"><offsets xml_i="21808" xml_f="21809" txt_i="12810" txt_f="12811">X</offsets></td><td align="center"><offsets xml_i="21833" xml_f="21834" txt_i="12812" txt_f="12813">X</offsets></td><td align="center"><offsets xml_i="21858" xml_f="21859" txt_i="12814" txt_f="12815">X</offsets></td><td align="center"><offsets xml_i="21883" xml_f="21884" txt_i="12816" txt_f="12817">X</offsets></td></tr><tr><td align="left"><offsets xml_i="21915" xml_f="21948" txt_i="12818" txt_f="12851">Use of professional care services</offsets></td><td align="left"><offsets xml_i="21970" xml_f="22004" txt_i="12852" txt_f="12886">Diary and health care registration</offsets></td><td align="center"><offsets xml_i="22028" xml_f="22029" txt_i="12887" txt_f="12888">X</offsets></td><td align="center"><offsets xml_i="22053" xml_f="22054" txt_i="12889" txt_f="12890">X</offsets></td><td align="center"><offsets xml_i="22078" xml_f="22079" txt_i="12891" txt_f="12892">X</offsets></td><td align="center"><offsets xml_i="22103" xml_f="22104" txt_i="12893" txt_f="12894">X</offsets></td><td align="center"><offsets xml_i="22128" xml_f="22129" txt_i="12895" txt_f="12896">X</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="22175" xml_f="22269" txt_i="12897" txt_f="12991">* European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30</offsets></p><p><offsets xml_i="22276" xml_f="22373" txt_i="12992" txt_f="13089">** Rotterdam Symptom Checklist, overall question ("overall, how did you feel over the past week")</offsets></p><p><offsets xml_i="22380" xml_f="22411" txt_i="13090" txt_f="13121">*** Short Fatigue Questionnaire</offsets></p><p><offsets xml_i="22418" xml_f="22459" txt_i="13122" txt_f="13163">**** Groningen Activity Restriction Scale</offsets></p></table-wrap-foot></table-wrap><p><italic><offsets xml_i="22505" xml_f="22521" txt_i="13164" txt_f="13180">Quality of life </offsets></italic><offsets xml_i="22530" xml_f="22613" txt_i="13180" txt_f="13263">was assessed using the EORTC Quality of Life Questionnaire (QLQ-C30, version 3.0) [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="22645" xml_f="22647" txt_i="13263" txt_f="13265">11</offsets></xref><offsets xml_i="22654" xml_f="22655" txt_i="13265" txt_f="13266">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="22687" xml_f="22689" txt_i="13266" txt_f="13268">12</offsets></xref><offsets xml_i="22696" xml_f="23848" txt_i="13268" txt_f="14420">]. The QLQ-C30 is a 30-item cancer-specific core questionnaire that addresses various domains of QoL. It contains five functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning and social functioning), three symptom scales (fatigue, pain and nausea/vomiting), two items assessing global health and quality of life, and a number of single items addressing various symptoms (constipation, diarrhoea, dyspnea, anorexia and insomnia) and perceived financial impact. All items are scored on a 4-point Likert-type scale. The content areas covered by this questionnaire reflect the multi-dimensionality of the quality of life construct. The EORTC QLQ has been extensively used for assessing health-related quality of life in patients with a wide range of cancers. Studies in patients with advanced cancer with a short life expectancy showed that the questionnaire was well accepted, with a high completion rate and useful in detecting the effectiveness of palliative treatment over time. Results confirmed that the QLQ-C-30 is a reliable and valid measure of the quality of life in patients with advanced cancer [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="23880" xml_f="23882" txt_i="14420" txt_f="14422">13</offsets></xref><offsets xml_i="23889" xml_f="23890" txt_i="14422" txt_f="14423">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="23922" xml_f="23924" txt_i="14423" txt_f="14425">14</offsets></xref><offsets xml_i="23931" xml_f="23933" txt_i="14425" txt_f="14427">].</offsets></p><p><offsets xml_i="23940" xml_f="24199" txt_i="14428" txt_f="14687">In addition to the QLQ-C30, we used the overall question from the Rotterdam Symptom Checklist ("overall, how did you feel over the past week") as a general indicator of perceived QoL. The Rotterdam Symptom Checklist was originally validated in a Dutch study [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="24231" xml_f="24233" txt_i="14687" txt_f="14689">15</offsets></xref><offsets xml_i="24240" xml_f="24310" txt_i="14689" txt_f="14759">] and has since then been used in numerous studies in cancer patients.</offsets></p><p><italic><offsets xml_i="24325" xml_f="24333" txt_i="14760" txt_f="14768">Fatigue </offsets></italic><offsets xml_i="24342" xml_f="24467" txt_i="14768" txt_f="14893">was measured by the Short Fatigue Questionnaire (SFQ). The SFQ is a reliable and simple instrument to assess bodily fatigue [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="24499" xml_f="24501" txt_i="14893" txt_f="14895">16</offsets></xref><offsets xml_i="24508" xml_f="24594" txt_i="14895" txt_f="14981">]. The questionnaire comprises 4 items. Each item is scored on a 7-point Likert scale.</offsets></p><p><italic><offsets xml_i="24609" xml_f="24630" txt_i="14982" txt_f="15003">Physical restriction </offsets></italic><offsets xml_i="24639" xml_f="24704" txt_i="15003" txt_f="15068">was assessed by the Groningen Activity Restraint Scale (GARS-4) [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="24736" xml_f="24738" txt_i="15068" txt_f="15070">17</offsets></xref><offsets xml_i="24745" xml_f="25215" txt_i="15070" txt_f="15540">]. The GARS-4 was developed to assess disability in the domains of personal care (11 items) and domestic activities (7 items). Studies in persons receiving home care, healthy seniors, patients with recent diagnosed cancer, multiple sclerosis, or rheumatoid arthritis showed that the GARS is an easy to administer, reliable, and valid measure for assessing disability in the domains of ADL (Activities of Daily Living) and IADL (Instrumental Activities of Daily Living) [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="25247" xml_f="25249" txt_i="15540" txt_f="15542">18</offsets></xref><offsets xml_i="25256" xml_f="25257" txt_i="15542" txt_f="15543">,</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="25289" xml_f="25291" txt_i="15543" txt_f="15545">19</offsets></xref><offsets xml_i="25298" xml_f="25300" txt_i="15545" txt_f="15547">].</offsets></p></sec><sec><title><offsets xml_i="25322" xml_f="25348" txt_i="15549" txt_f="15575">Secondary outcome measures</offsets></title><p><italic><offsets xml_i="25367" xml_f="25394" txt_i="15576" txt_f="15603">Secondary outcome measures </offsets></italic><offsets xml_i="25403" xml_f="25408" txt_i="15603" txt_f="15608">were:</offsets></p><p><offsets xml_i="25415" xml_f="25417" txt_i="15609" txt_f="15611">- </offsets><italic><offsets xml_i="25425" xml_f="25433" txt_i="15611" txt_f="15619">Appetite</offsets></italic><offsets xml_i="25442" xml_f="25860" txt_i="15619" txt_f="16037">, assessed by four 100 mm visual analogue scales (VAS) related to hunger and satiety with words anchored at each end expressing the most positive or negative sensation. Some studies have investigated the correlation between hunger ratings and energy intake, i.e. the validity of the appetite ratings. Many of these have failed to demonstrate such a relationship, while others have found that there was an association [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="25892" xml_f="25894" txt_i="16037" txt_f="16039">20</offsets></xref><offsets xml_i="25901" xml_f="25902" txt_i="16039" txt_f="16040">,</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="25934" xml_f="25936" txt_i="16040" txt_f="16042">21</offsets></xref><offsets xml_i="25943" xml_f="26060" txt_i="16042" txt_f="16159">]. Results obtained from VAS yield the most valuable information when combined with other aspects of energy balance [</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="26092" xml_f="26094" txt_i="16159" txt_f="16161">22</offsets></xref><offsets xml_i="26101" xml_f="26103" txt_i="16161" txt_f="16163">].</offsets></p><p><offsets xml_i="26110" xml_f="26112" txt_i="16164" txt_f="16166">- </offsets><italic><offsets xml_i="26120" xml_f="26139" txt_i="16166" txt_f="16185">Nutritional intake </offsets></italic><offsets xml_i="26148" xml_f="26633" txt_i="16185" txt_f="16670">was assessed by a 3-day food diary. Patients were taught to keep records, in portion sizes, of all the foods they had eaten on several days of the study. The portion sizes were described in household measures using the utensils commonly found in their homes. These household measures were quantified by volume by the investigator. In general, a 3-day record, randomized to cover seasonal and weekday variations is recommended to assess mean food consumption of a group of individuals [</offsets><xref ref-type="bibr" rid="B23"><offsets xml_i="26665" xml_f="26667" txt_i="16670" txt_f="16672">23</offsets></xref><offsets xml_i="26674" xml_f="26993" txt_i="16672" txt_f="16991">]. A review about the validity of self-reported energy intake showed that energy intake derived from all methods of food recording can be an imprecise measure that is substantially under-reporting in groups including adults, children and adolescents, obese persons, athletes, military personnel and trekking explorers [</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="27025" xml_f="27027" txt_i="16991" txt_f="16993">24</offsets></xref><offsets xml_i="27034" xml_f="27086" txt_i="16993" txt_f="17045">]. No data about patients with cancer are available.</offsets></p><p><offsets xml_i="27093" xml_f="27095" txt_i="17046" txt_f="17048">- </offsets><italic><offsets xml_i="27103" xml_f="27113" txt_i="17048" txt_f="17058">Medication</offsets></italic><offsets xml_i="27122" xml_f="27171" txt_i="17058" txt_f="17107">; changes were registered during each home visit.</offsets></p><p><offsets xml_i="27178" xml_f="27180" txt_i="17108" txt_f="17110">- </offsets><italic><offsets xml_i="27188" xml_f="27199" txt_i="17110" txt_f="17121">Body height</offsets></italic><offsets xml_i="27208" xml_f="27249" txt_i="17121" txt_f="17162">, measured to the nearest 0.1 centimeter.</offsets></p><p><offsets xml_i="27256" xml_f="27258" txt_i="17163" txt_f="17165">- </offsets><italic><offsets xml_i="27266" xml_f="27278" txt_i="17165" txt_f="17177">Body weight </offsets></italic><offsets xml_i="27287" xml_f="27408" txt_i="17177" txt_f="17298">was measured without shoes, using an electronic weighing scale (Soehnle 7407 Translucia, Germany) to the nearest 0.05 kg.</offsets></p><p><offsets xml_i="27415" xml_f="27417" txt_i="17299" txt_f="17301">- </offsets><italic><offsets xml_i="27425" xml_f="27453" txt_i="17301" txt_f="17329">Triceps skin fold thickness </offsets></italic><offsets xml_i="27462" xml_f="27502" txt_i="17329" txt_f="17369">was measured in duplicate with a Holtain</offsets><sup><offsets xml_i="27507" xml_f="27509" txt_i="17369" txt_f="17371">Â® </offsets></sup><offsets xml_i="27515" xml_f="27679" txt_i="17371" txt_f="17535">skinfold caliper (CMS weighing equipment LTD, London UK) to calculate total body fat mass (FM) using the age- and gender-specific tables from Durnin and Womersley [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="27711" xml_f="27713" txt_i="17535" txt_f="17537">25</offsets></xref><offsets xml_i="27720" xml_f="27799" txt_i="17537" txt_f="17616">]. Fat-free mass (FFM) was calculated by subtracting fat mass from body weight.</offsets></p><p><offsets xml_i="27806" xml_f="27808" txt_i="17617" txt_f="17619">- </offsets><italic><offsets xml_i="27816" xml_f="27844" txt_i="17619" txt_f="17647">Mid-upper arm circumference </offsets></italic><offsets xml_i="27853" xml_f="27922" txt_i="17647" txt_f="17716">of the dominant arm was measured with a flexible measuring tape, and </offsets><italic><offsets xml_i="27930" xml_f="27946" txt_i="17716" txt_f="17732">arm muscle area </offsets></italic><offsets xml_i="27955" xml_f="28025" txt_i="17732" txt_f="17802">derived using the equation: (arm circumference - Ï Ã triceps skinfold)</offsets><sup><offsets xml_i="28030" xml_f="28031" txt_i="17802" txt_f="17803">2</offsets></sup><offsets xml_i="28037" xml_f="28043" txt_i="17803" txt_f="17809">/4 Ï [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="28075" xml_f="28077" txt_i="17809" txt_f="17811">26</offsets></xref><offsets xml_i="28084" xml_f="28178" txt_i="17811" txt_f="17905">]. Arm muscle area gives an indication of the body's muscle mass as its main protein reserve [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="28210" xml_f="28212" txt_i="17905" txt_f="17907">26</offsets></xref><offsets xml_i="28219" xml_f="28221" txt_i="17907" txt_f="17909">].</offsets></p><p><offsets xml_i="28228" xml_f="28230" txt_i="17910" txt_f="17912">- </offsets><italic><offsets xml_i="28238" xml_f="28254" txt_i="17912" txt_f="17928">Muscle strength </offsets></italic><offsets xml_i="28263" xml_f="28405" txt_i="17928" txt_f="18070">of two major muscle groups (i.e. elbow flexor and knee extensor muscles) were assessed at the dominant arm and leg using a hand/held Microfet2</offsets><sup><offsets xml_i="28410" xml_f="28412" txt_i="18070" txt_f="18072">Â® </offsets></sup><offsets xml_i="28418" xml_f="28589" txt_i="18072" txt_f="18243">dynamometer (Biometrics Europe BV, Almere, The Netherlands). This technique has been validated in several patient groups, mostly in patients whit limited muscle strength [</offsets><xref ref-type="bibr" rid="B27"><offsets xml_i="28621" xml_f="28623" txt_i="18243" txt_f="18245">27</offsets></xref><offsets xml_i="28630" xml_f="28631" txt_i="18245" txt_f="18246">-</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="28663" xml_f="28665" txt_i="18246" txt_f="18248">29</offsets></xref><offsets xml_i="28672" xml_f="29438" txt_i="18248" txt_f="19014">]. The patient while sitting exerts a maximal force with the 90Â° flexed elbow, while the examiner pushes with the dynamometer against the patients' thumb pad until muscle strength is overcome (break test). Similarly, the patient exerts a maximal force with the 90Â° flexed knee, while the examiner pushes with the dynamometer against the patients' ankle until muscle strength is overcome. The strength of both muscle groups is measured twice at an interval of approximately one minute. Muscle strength is expressed in Newtonmeter (Nm) units and calculated by dividing the measured mean strength (dynamometer reading) by the distance from dynamometer position point to the medial humeral epicondylus medialis (elbow) and the medial femoral epicondylus medialis (knee).</offsets></p><p><italic><offsets xml_i="29453" xml_f="29471" txt_i="19015" txt_f="19033">Handgrip strength </offsets></italic><offsets xml_i="29480" xml_f="29795" txt_i="19033" txt_f="19348">of the dominant hand was measured using a JAMAR hydraulic hand dynamometer (Saehan Corp. Masan, Korea). Handgrip strength is a simple, quick, easily performed, and readily available bedside test. Studies in several population groups showed strong positive correlations between handgrip strength and lean body mass [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="29827" xml_f="29829" txt_i="19348" txt_f="19350">30</offsets></xref><offsets xml_i="29836" xml_f="29917" txt_i="19350" txt_f="19431">]. Furthermore, handgrip strength is correlated with total body muscle strength [</offsets><xref ref-type="bibr" rid="B31"><offsets xml_i="29949" xml_f="29951" txt_i="19431" txt_f="19433">31</offsets></xref><offsets xml_i="29958" xml_f="29960" txt_i="19433" txt_f="19435">].</offsets></p><p><offsets xml_i="29967" xml_f="30128" txt_i="19436" txt_f="19597">In order to exclude inter-observer variability, longitudinal anthropometric and muscle strength measurements in each patient were performed by the same observer.</offsets></p><sec><title><offsets xml_i="30144" xml_f="30160" txt_i="19598" txt_f="19614">Caregiver burden</offsets></title><p><offsets xml_i="30171" xml_f="30810" txt_i="19615" txt_f="20254">The second study objective was to evaluate whether ATP infusions could relieve family caregiver burden and reduce the use of professional health care services. Caregiver burden was measured at two levels: 1. informal care; 2. professional care. To measure caregiver burden we used the GARS-4. For each item it must be marked whether the patient, the family caregivers or health care professionals carried out the activities (not at all, partly, completely). Use of medical care services (hospital admissions, outpatient clinic visits, general practitioner contacts), and home care (both domestic and nursing care) was recorded every visit.</offsets></p></sec><sec><title><offsets xml_i="30832" xml_f="30850" txt_i="20256" txt_f="20274">Process evaluation</offsets></title><p></p></sec></sec></sec><sec><title><offsets xml_i="30895" xml_f="30935" txt_i="20279" txt_f="20319">Data management and statistical analysis</offsets></title><p><offsets xml_i="30946" xml_f="31036" txt_i="20320" txt_f="20410">Data were entered using Microsoft Access 2000 and checked for errors by double data entry.</offsets></p><p><offsets xml_i="31043" xml_f="31639" txt_i="20411" txt_f="21007">Comparability of baseline characteristics among the ATP and control group were assessed for age, gender, tumor type, performance status and weight loss by descriptive statistics (SPSS). Differences over time in the two groups were analyzed according to the 'intention-to-treat' principle by repeated-measures analysis of covariance with the use of the linear regression model. These analyses were performed with the SAS procedure Proc Mixed, with the use of the independence working correlation structure. Multivariate analyses were used to adjust the estimated effects for potential confounders.</offsets></p><sec><title><offsets xml_i="31655" xml_f="31684" txt_i="21008" txt_f="21037">Sample size/power calculation</offsets></title><p><offsets xml_i="31695" xml_f="31741" txt_i="21038" txt_f="21084">Data from a previous study in NSCLC patients [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="31772" xml_f="31773" txt_i="21084" txt_f="21085">5</offsets></xref><offsets xml_i="31780" xml_f="32350" txt_i="21085" txt_f="21655">] (related to 8 weeks of follow-up) were used to calculate the sample size needed to detect clinically relevant effects of ATP infusion on the primary outcome measures fatigue and physical restriction. For both measures we assumed a mean deterioration in the control group similar to the one observed in the previous study. In the experimental group, based on an expected worse condition of patients in the present study when compared with our previous study in NSCLC patients, we used a conservative estimate. Based on our previous randomized trial with ATP infusions [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="32381" xml_f="32382" txt_i="21655" txt_f="21656">5</offsets></xref><offsets xml_i="32389" xml_f="32940" txt_i="21656" txt_f="22207">], it was calculated that a total of 60 patients would be sufficient to detect a between-group difference of 0.65 units in fatigue on a 4-point scale after 8 weeks with a power of 90% and a two-tailed alpha of 0.05. An uncertain factor in sample size calculation was the drop-out rate which was estimated to vary from 25â40%. Assuming a drop-out rate of 25% during the 8-week follow-up period, a total of 80 patients (40 patients per treatment arm) would be needed; in case of higher drop out (e.g. 40%) recruitment would be increased to 100 patients.</offsets></p></sec></sec></sec><sec><title><offsets xml_i="32974" xml_f="32984" txt_i="22211" txt_f="22221">Discussion</offsets></title><p><offsets xml_i="32995" xml_f="33471" txt_i="22222" txt_f="22698">From April 2002 through October 2006, a total of 100 patients have been randomized: 10 patients in 2002, 5 in 2003, 22 in 2004, 40 in 2005, and 23 in 2006. The study was closed on October 31 2006. Follow-up of patients will be completed in December 2006. At the time of writing, five patients are still in follow up. Of the 95 patients who have completed the study, 69 (73%) have completed four weeks of follow-up, and 53 (56%) have completed the full eight-week study period.</offsets></p><p><offsets xml_i="33478" xml_f="33944" txt_i="22699" txt_f="23165">We hope this study will demonstrate that ATP infusions leads to a reduction of frequently reported complaints in terminally ill cancer patients, for which no effective treatment is yet available. In addition, we hope to show that ATP-infusions can be administered safely in a home care setting. In case of positive findings, this trial may be a first step towards implementation of ATP infusions in integrated palliative care. The first results are expected in 2007.</offsets></p></sec><sec><title><offsets xml_i="33966" xml_f="33985" txt_i="23167" txt_f="23186">Competing interests</offsets></title><p><offsets xml_i="33996" xml_f="34056" txt_i="23187" txt_f="23247">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="34078" xml_f="34100" txt_i="23249" txt_f="23271">Authors' contributions</offsets></title><p><offsets xml_i="34111" xml_f="34357" txt_i="23272" txt_f="23518">ER, PH, CS, MB, RW, LA and PD participated in the design of the study and SB, PH, MB, LA, BB, AG in the acquisition of data. SB drafted the manuscript with imput from all other authors. All authors read, revised and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="34379" xml_f="34402" txt_i="23520" txt_f="23543">Pre-publication history</offsets></title><p><offsets xml_i="34413" xml_f="34477" txt_i="23544" txt_f="23608">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2458/7/4/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by a grant within the programme "Palliative Care in the Terminal Phase" of the Netherlands Organisation for Health Research and Development (ZonMw), and by the 'Stichting Nationaal Fonds Tegen Kanker' (Foundation National Fund against Cancer), The Netherlands. The authors would like to thank the oncologists, pulmonologists and general practitioners for participating in patient recruitment. We also would like to thank Nicole Wijckmans for the assistance with outcome measurements.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sepulveda</surname><given-names>C</given-names></name><name><surname>Marlin</surname><given-names>A</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name></person-group><article-title>Palliative Care: the World Health Organization's global perspective</article-title><source>J Pain Symptom Manage</source><year>2002</year><volume>24</volume><fpage>91</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">12231124</pub-id><pub-id pub-id-type="doi">10.1016/S0885-3924(02)00440-2</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundh Hagelin</surname><given-names>C</given-names></name><name><surname>Seiger</surname><given-names>A</given-names></name><name><surname>Furst</surname><given-names>CJ</given-names></name></person-group><article-title>Quality of life in terminal care--with special reference to age, gender and marital status</article-title><source>Support Care Cancer</source><year>2006</year><volume>14</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">16189646</pub-id><pub-id pub-id-type="doi">10.1007/s00520-005-0886-4</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Courtens</surname><given-names>AM</given-names></name></person-group><article-title>Kenmerken van zorg en kwaliteit van leven bij patiÃ«nten met kanker</article-title><source>Proefschrift</source><year>1993</year><volume>Universitaire Pers Maastricht</volume></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agteresch</surname><given-names>HJ</given-names></name><name><surname>Dagnelie</surname><given-names>PC</given-names></name><name><surname>van den Berg</surname><given-names>JW</given-names></name><name><surname>Wilson</surname><given-names>JH</given-names></name></person-group><article-title>Adenosine triphosphate: established and potential clinical applications</article-title><source>Drugs</source><year>1999</year><volume>58</volume><fpage>211</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">10473017</pub-id><pub-id pub-id-type="doi">10.2165/00003495-199958020-00002</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agteresch</surname><given-names>HJ</given-names></name><name><surname>Dagnelie</surname><given-names>PC</given-names></name><name><surname>van Der Gaast</surname><given-names>A</given-names></name><name><surname>Stijnen</surname><given-names>T</given-names></name><name><surname>Wilson</surname><given-names>JH</given-names></name></person-group><article-title>Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer</article-title><source>J Natl Cancer Inst</source><year>2000</year><volume>92</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="pmid">10675381</pub-id><pub-id pub-id-type="doi">10.1093/jnci/92.4.321</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agteresch</surname><given-names>HJ</given-names></name><name><surname>Dagnelie</surname><given-names>PC</given-names></name><name><surname>Rietveld</surname><given-names>T</given-names></name><name><surname>van den Berg</surname><given-names>JW</given-names></name><name><surname>Danser</surname><given-names>AH</given-names></name><name><surname>Wilson</surname><given-names>JH</given-names></name></person-group><article-title>Pharmacokinetics of intravenous ATP in cancer patients</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>56</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">10853877</pub-id><pub-id pub-id-type="doi">10.1007/s002280050719</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Freilich</surname><given-names>A</given-names></name><name><surname>Tepper</surname><given-names>D</given-names></name></person-group><article-title>Adenosine and its cardiovascular effects</article-title><source>Am Heart J</source><year>1992</year><volume>123</volume><fpage>1324</fpage><lpage>1328</lpage><pub-id pub-id-type="pmid">1575151</pub-id><pub-id pub-id-type="doi">10.1016/0002-8703(92)91040-8</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name></person-group><article-title>[Electrophysiological effects of different dosage of adenosine triphosphate on normal sinoatrial and atrioventricular node]</article-title><source>Chung Hua Hsin Hsueh Kuan Ping Tsa Chih</source><year>1992</year><volume>20</volume><fpage>98</fpage><lpage>100, 134</lpage><pub-id pub-id-type="pmid">1473491</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Halteren</surname><given-names>HK</given-names></name><name><surname>Bongaerts</surname><given-names>GP</given-names></name><name><surname>Wagener</surname><given-names>DJ</given-names></name></person-group><article-title>Cancer cachexia: what is known about its etiology and what should be the current treatment approach?</article-title><source>Anticancer Res</source><year>2003</year><volume>23</volume><fpage>5111</fpage><lpage>5115</lpage><pub-id pub-id-type="pmid">14981975</pub-id></citation></ref><ref id="B10"><citation citation-type="other"><article-title>National Cancer Institute. Common Toxicity Criteria, version 2.0. Publish date: April 30, 1999.</article-title></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Ahmedzai</surname><given-names>S</given-names></name><name><surname>Bergman</surname><given-names>B</given-names></name><name><surname>Bullinger</surname><given-names>M</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Duez</surname><given-names>NJ</given-names></name><name><surname>Filiberti</surname><given-names>A</given-names></name><name><surname>Flechtner</surname><given-names>H</given-names></name><name><surname>Fleishman</surname><given-names>SB</given-names></name><name><surname>de Haes</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology</article-title><source>J Natl Cancer Inst</source><year>1993</year><volume>85</volume><fpage>365</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">8433390</pub-id><pub-id pub-id-type="doi">10.1093/jnci/85.5.365</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>NK</given-names></name><name><surname>Cull</surname><given-names>AM</given-names></name><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Sprangers</surname><given-names>MAG</given-names></name></person-group><article-title>The European Organization for Research and Treatment of Canncer (EORTC) Modular Approach to Quality of Life Assessment in Oncology: An Update</article-title><source>Quality of Life and Pharmacoeconomics in Clinical Trials</source><year>1996</year><volume>Second Edition, Chapter 21</volume><fpage>179</fpage><lpage>189</lpage></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kyriaki</surname><given-names>M</given-names></name><name><surname>Eleni</surname><given-names>T</given-names></name><name><surname>Efi</surname><given-names>P</given-names></name><name><surname>Ourania</surname><given-names>K</given-names></name><name><surname>Vassilios</surname><given-names>S</given-names></name><name><surname>Lambros</surname><given-names>V</given-names></name></person-group><article-title>The EORTC core quality of life questionnaire (QLQ-C30, version 3.0) in terminally ill cancer patients under palliative care: validity and reliability in a Hellenic sample</article-title><source>Int J Cancer</source><year>2001</year><volume>94</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">11668488</pub-id><pub-id pub-id-type="doi">10.1002/ijc.1439</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaasa</surname><given-names>S</given-names></name><name><surname>Bjordal</surname><given-names>K</given-names></name><name><surname>Aaronson</surname><given-names>N</given-names></name><name><surname>Moum</surname><given-names>T</given-names></name><name><surname>Wist</surname><given-names>E</given-names></name><name><surname>Hagen</surname><given-names>S</given-names></name><name><surname>Kvikstad</surname><given-names>A</given-names></name></person-group><article-title>The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy</article-title><source>Eur J Cancer</source><year>1995</year><volume>31a</volume><fpage>2260</fpage><lpage>2263</lpage><pub-id pub-id-type="pmid">8652253</pub-id><pub-id pub-id-type="doi">10.1016/0959-8049(95)00296-0</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Haes</surname><given-names>JC</given-names></name><name><surname>van Knippenberg</surname><given-names>FC</given-names></name><name><surname>Neijt</surname><given-names>JP</given-names></name></person-group><article-title>Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist</article-title><source>Br J Cancer</source><year>1990</year><volume>62</volume><fpage>1034</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">2257209</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberts</surname><given-names>M</given-names></name><name><surname>Smets</surname><given-names>EM</given-names></name><name><surname>Vercoulen</surname><given-names>JH</given-names></name><name><surname>Garssen</surname><given-names>B</given-names></name><name><surname>Bleijenberg</surname><given-names>G</given-names></name></person-group><article-title>'Verkorte vermoeidheidsvragenlijst': een praktisch hulpmiddel bij het scoren van vermoeidheid</article-title><source>NTVG</source><year>1997</year><volume>141</volume><fpage>1526</fpage><lpage>1530</lpage></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>GI</given-names></name><name><surname>Miedema</surname><given-names>I</given-names></name><name><surname>Ormel</surname><given-names>J</given-names></name><name><surname>Molenaar</surname><given-names>W</given-names></name></person-group><article-title>The assessment of disability with the Groningen Activity Restriction Scale. Conceptual framework and psychometric properties</article-title><source>Soc Sci Med</source><year>1996</year><volume>43</volume><fpage>1601</fpage><lpage>1610</lpage><pub-id pub-id-type="pmid">8961404</pub-id><pub-id pub-id-type="doi">10.1016/S0277-9536(96)00057-3</pub-id></citation></ref><ref id="B18"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kempen</surname><given-names>GIJM</given-names></name><name><surname>Doeglas</surname><given-names>DM</given-names></name><name><surname>Suurmeijer</surname><given-names>TPBM</given-names></name></person-group><source>Groningen Activiteiten Restrictie Schaal (GARS): een handleiding</source><year>1993</year><publisher-name>Groningen, Rijksuniversiteit Groningen</publisher-name></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suurmeijer</surname><given-names>TP</given-names></name><name><surname>Doeglas</surname><given-names>DM</given-names></name><name><surname>Moum</surname><given-names>T</given-names></name><name><surname>Briancon</surname><given-names>S</given-names></name><name><surname>Krol</surname><given-names>B</given-names></name><name><surname>Sanderman</surname><given-names>R</given-names></name><name><surname>Guillemin</surname><given-names>F</given-names></name><name><surname>Bjelle</surname><given-names>A</given-names></name><name><surname>van den Heuvel</surname><given-names>WJ</given-names></name></person-group><article-title>The Groningen Activity Restriction Scale for measuring disability: its utility in international comparisons</article-title><source>Am J Public Health</source><year>1994</year><volume>84</volume><fpage>1270</fpage><lpage>1273</lpage><pub-id pub-id-type="pmid">8059884</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Graaf</surname><given-names>C</given-names></name></person-group><article-title>The validity of appetite ratings</article-title><source>Appetite</source><year>1993</year><volume>21</volume><fpage>156</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">8285654</pub-id><pub-id pub-id-type="doi">10.1016/0195-6663(93)90008-8</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raben</surname><given-names>A</given-names></name><name><surname>Tagliabue</surname><given-names>A</given-names></name><name><surname>Astrup</surname><given-names>A</given-names></name></person-group><article-title>The reproducibility of subjective appetite scores</article-title><source>Br J Nutr</source><year>1995</year><volume>73</volume><fpage>517</fpage><lpage>530</lpage><pub-id pub-id-type="pmid">7794869</pub-id><pub-id pub-id-type="doi">10.1079/BJN19950056</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stubbs</surname><given-names>RJ</given-names></name><name><surname>Hughes</surname><given-names>DA</given-names></name><name><surname>Johnstone</surname><given-names>AM</given-names></name><name><surname>Rowley</surname><given-names>E</given-names></name><name><surname>Reid</surname><given-names>C</given-names></name><name><surname>Elia</surname><given-names>M</given-names></name><name><surname>Stratton</surname><given-names>R</given-names></name><name><surname>Delargy</surname><given-names>H</given-names></name><name><surname>King</surname><given-names>N</given-names></name><name><surname>Blundell</surname><given-names>JE</given-names></name></person-group><article-title>The use of visual analogue scales to assess motivation to eat in human subjects: a review of their reliability and validity with an evaluation of new hand-held computerized systems for temporal tracking of appetite ratings</article-title><source>Br J Nutr</source><year>2000</year><volume>84</volume><fpage>405</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">11103211</pub-id></citation></ref><ref id="B23"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Bingham S.A.</surname><given-names>NM</given-names><suffix>Paul A.A, Haraldsdottir J, Bjorge Loken E, van Staveren W.A.</suffix></name></person-group><person-group person-group-type="editor"><name><surname>Cameron M.E SWA</surname></name></person-group><article-title>Methods for data collection at an individual level.</article-title><source>Manual on methodology for food consumption studies</source><year>1988</year><publisher-name>Oxford, Oxford University Press</publisher-name><fpage>53</fpage><lpage>106</lpage></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>RJ</given-names></name><name><surname>Davies</surname><given-names>PS</given-names></name></person-group><article-title>The validity of self-reported energy intake as determined using the doubly labelled water technique</article-title><source>Br J Nutr</source><year>2001</year><volume>85</volume><fpage>415</fpage><lpage>430</lpage><pub-id pub-id-type="pmid">11348556</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durnin</surname><given-names>JV</given-names></name><name><surname>Womersley</surname><given-names>J</given-names></name></person-group><article-title>Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years</article-title><source>Br J Nutr</source><year>1974</year><volume>32</volume><fpage>77</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">4843734</pub-id><pub-id pub-id-type="doi">10.1079/BJN19740060</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gurney</surname><given-names>JM</given-names></name><name><surname>Jelliffe</surname><given-names>DB</given-names></name></person-group><article-title>Arm anthropometry in nutritional assessment: nomogram for rapid calculation of muscle circumference and cross-sectional muscle and fat areas</article-title><source>Am J Clin Nutr</source><year>1973</year><volume>26</volume><fpage>912</fpage><lpage>915</lpage><pub-id pub-id-type="pmid">4727749</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bohannon</surname><given-names>RW</given-names></name></person-group><article-title>Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years</article-title><source>Arch Phys Med Rehabil</source><year>1997</year><volume>78</volume><fpage>26</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">9014953</pub-id><pub-id pub-id-type="doi">10.1016/S0003-9993(97)90005-8</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwoh</surname><given-names>CK</given-names></name><name><surname>Petrick</surname><given-names>MA</given-names></name><name><surname>Munin</surname><given-names>MC</given-names></name></person-group><article-title>Inter-rater reliability for function and strength measurements in the acute care hospital after elective hip and knee arthroplasty</article-title><source>Arthritis Care Res</source><year>1997</year><volume>10</volume><fpage>128</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">9313401</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>MA</given-names></name><name><surname>Doherty</surname><given-names>TJ</given-names></name></person-group><article-title>Reliability of hand-held dynamometry in assessment of knee extensor strength after hip fracture</article-title><source>Am J Phys Med Rehabil</source><year>2004</year><volume>83</volume><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">15502733</pub-id><pub-id pub-id-type="doi">10.1097/01.PHM.0000143405.17932.78</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>AY</given-names></name><name><surname>Sea</surname><given-names>MM</given-names></name><name><surname>Ho</surname><given-names>ZS</given-names></name><name><surname>Lui</surname><given-names>SF</given-names></name><name><surname>Li</surname><given-names>PK</given-names></name><name><surname>Woo</surname><given-names>J</given-names></name></person-group><article-title>Evaluation of handgrip strength as a nutritional marker and prognostic indicator in peritoneal dialysis patients</article-title><source>Am J Clin Nutr</source><year>2005</year><volume>81</volume><fpage>79</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">15640464</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rantanen</surname><given-names>T</given-names></name><name><surname>Volpato</surname><given-names>S</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Heikkinen</surname><given-names>E</given-names></name><name><surname>Fried</surname><given-names>LP</given-names></name><name><surname>Guralnik</surname><given-names>JM</given-names></name></person-group><article-title>Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism</article-title><source>J Am Geriatr Soc</source><year>2003</year><volume>51</volume><fpage>636</fpage><lpage>641</lpage><pub-id pub-id-type="pmid">12752838</pub-id><pub-id pub-id-type="doi">10.1034/j.1600-0579.2003.00207.x</pub-id></citation></ref></ref-list></back></article>